A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

Study Summary

This study evaluates the safety, pharmacokinetics, and efficacy of BP1002 (L-Bcl-2) antisense oligonucleotide in patients with advanced lymphoid malignancies. Up to 12 evaluable patients with a diagnosis of relapsed or refractory lymphoid malignancies are expected to participate.

Conditions

Mantle Cell Lymphoma Peripheral T-cell Lymphoma (PTCL)Cutaneous T-cell Lymphoma (CTCL)Chronic Lymphocytic Leukemia (CLL)Small Lymphocytic Lymphoma (SLL)Follicular Lymphoma Marginal Zone Lymphoma Hodgkin Lymphoma Waldenstrom Macroglobulinemia DLBCL

Interventions / Drugs

L-Bcl-2 antisense oligonucleotide

View on ClinicalTrials.gov ↗

Sponsor

Study Details

Enrollment30 participants

Primary Completion—

Lead SponsorBio-Path Holdings, Inc.

Data Retrieved2026-04-11 04:08:24.860976+00:00

Not financial advice. BiotechSigns data is sourced from ClinicalTrials.gov, SEC EDGAR, and other public databases for research and informational purposes only. It does not constitute investment recommendations. Always do your own due diligence before making investment decisions.